Cocrystal Pharma (COCP)
(Delayed Data from NSDQ)
$2.35 USD
0.00 (0.00%)
Updated Jul 19, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
COCP 2.35 0.00(0.00%)
Will COCP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for COCP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COCP
Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy?
COCP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for COCP
Cocrystal Pharma (COCP) Receives a Buy from Noble Financial
Cocrystal Pharma reports results from SAD cohorts of Phase 1 study with CDI-988
Noble Financial Sticks to Its Buy Rating for Cocrystal Pharma (COCP)
Cocrystal Pharma’s Promising Antiviral Candidate for Influenza A
New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows